As of August 12, 2026, federal medical marijuana laws have significantly changed. Federal law now recognizes a limited Schedule III medical-marijuana pathway. However, marijuana has not been legalized Federally.
State-licensed medical marijuana is now Schedule III
Effective April, 2026, the U.S. Attorney General and DEA placed Cannabis in the Schedule III group. The Schedule III group includes FDA-approved products now containing marijuana, marijuana, extracts, and naturally derived delta-9 THC subject to a qualifying state medical-marijuana license.
The new regulations appear in 21 C.F.R. §§ 1301.13 and 1308.13. Federal Register final rule, 91 Fed. Reg. 22714; current Schedule III regulation. Under the rule, state-licensed medical cultivators, distributors, and dispensaries may obtain expedited DEA registration. Registered dispensaries may dispense marijuana to people authorized under state medical-marijuana law. A state medical-marijuana certification can substitute for a traditional prescription if it contains the required patient and practitioner information. A timely applicant may operate under transitional rules while DEA reviews its registration.
However, a state license alone does not indefinitely replace DEA registration.
Recreational and Unlicensed Marijuana Remain Schedule I
The new 2026 rule is product and license specific. It does not cover recreational marijuana, Black-market marijuana, marijuana outside a qualifying state medical system, most synthetically manufactured THC, or potentially home grown marijuana.
The proposal to move naturally derived marijuana from Schedule I to Schedule III underwent several hearings from June 29 through July 15, 2026. As of today, no published rule has been filed by the DEA. You can read about in this article.
Section 280E Tax Relief
Now that Marijuana is Schedule III, it has different IRS rules to follow. These rules are helpful to those in the cannabis industry. Medical licensees are no longer subject to Internal Revenue Code §280E, which applies only to trafficking in Schedule I or II substances.
A mixed medical and recreational business may still face §280E exposure for its recreational operations. The rule expressly cautions that particular tax liability remains subject to IRS and tax-counsel analysis.
Congressional Protection through September, 2026
In addition, protections remain in place for States that implement medical marijuana laws. Congress cannot spend money to prevent Illinois and the other listed jurisdictions from implementing their medical-marijuana laws. This protection expires with the fiscal-year appropriation unless Congress renews it. It does not protect conduct outside state law. Pub. L. 119-74, §531.
FDA law remains separate
Schedule III status does not mean dispensary marijuana is FDA approved. FDA still states that it has not approved cannabis itself to treat any disease. Ironically, it has approved Epidiolex, a cannabis derived CBD medication and other drugs. Some of these drugs include Marinol, Syndros, and Cesamet, which are synthetic cannabinoid-related drugs.
Medical claims for unapproved cannabis products can therefore still violate the Federal Food, Drug, and Cosmetic Act. FDA cannabis and drug-approval guidance.
New hemp/CBD restriction begin November, 2026
Section 781 of Public Law 119-37 will substantially narrow the federal definition of lawful hemp. Among other restrictions, a final hemp-derived product containing more than 0.4 milligrams of combined total THC and similar cannabinoids per container will be excluded from “hemp.” Many full-spectrum CBD products could consequently become controlled as marijuana. The change takes effect November 12, 2026. Pub. L. 119-37, §781.
The bottom line is that medical marijuana obtained through a qualifying state-licensed medical system now receives Schedule III treatment. Recreational, unlicensed, and some homegrown marijuana remain federally prohibited. Look at these articles for more marijuana research.